R&D Pipeline

CCrest Laboratories is a pioneer in developing novel psychotherapeutics in psychedelic psychotherapy.

At CCrest Laboratories, we're pioneering the research and development in the burgeoning field of psychedelic psychotherapy.

Supported by our Health Canada Controlled Drugs & Substances Licence, we're authorized to produce, possess, package, sell, import/export a range of psychedelic substances, including KETAMINE, LSD, MDMA, PSILOCYBIN, DMT, and MESCALINE.

These substances are at the forefront of our innovative treatment research in mental health care.

Psychedelic psychotherapy represents a groundbreaking approach in mental health treatment, offering new hope for conditions that have been resistant to conventional therapies.

Emerging research highlights the potential of psychedelic substances to effect significant and lasting changes in brain function and psychological well-being, providing relief from depression, anxiety, PTSD, and addiction among others.

Our Research Focus

Ketamine and Depression

Ketamine, long known for its anesthetic properties, has shown remarkable efficacy in treating depression, particularly in cases resistant to other treatments. Our research is exploring optimal formulation strategies and delivery methods to maximize therapeutic outcomes with minimal side effects.

LSD and Anxiety

Studies on LSD have revealed its potential to alleviate anxiety, especially in life-threatening conditions like terminal illness. CCrest's research aims to understand the potential for LSD to induce profound psychological changes, paving the way for therapeutic applications.


MDMA-assisted psychotherapy is a promising treatment for PTSD, offering enhanced emotional engagement without overwhelming stress. Our projects are focused on supporting partner's clinical trials that assess MDMA's efficacy and safety in therapeutic settings.

Psilocybin and Mental Health Disorders

Psilocybin, the psychoactive compound in magic mushrooms, has shown potential in treating a range of mental health disorders, including depression and anxiety. We're investigating the neurobiological effects of psilocybin and its ability to reset brain activity patterns associated with these conditions.

DMT and Mescaline

Our research extends to DMT and Mescaline, exploring their unique psychoactive properties and potential therapeutic benefits. By understanding their effects on consciousness and psychological states, we aim to uncover new pathways for treating mental health conditions.

Regulatory Compliance and Safety

Adhering to strict regulatory guidelines, our research is conducted with the utmost concern for safety and ethical considerations.

Each project under our Novel Psychotherapeutics program is designed to meet rigorous scientific standards, ensuring that our findings contribute to the responsible development and application of psychedelic-assisted therapies.


CCrest Laboratories is at the cutting edge of exploring and harnessing the therapeutic potential of psychedelics within the framework of psychedelic psychotherapy.

Through our comprehensive research and development efforts, supported by our Health Canada license, we aim to revolutionize the treatment of mental health disorders, offering new hope to individuals worldwide.